Zhejiang Jingxin Pharmaceutical Co., Ltd. Class A

As of June 30, 2026, Zhejiang Jingxin Pharmaceutical Co., Ltd. Class A carries a market capitalization of 10.75B, placing it among publicly traded companies globally. Its enterprise value stands at 9.89B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Zhejiang Jingxin Pharmaceutical Co., Ltd. Class A's next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, Zhejiang Jingxin Pharmaceutical Co., Ltd. Class A has 861.03M shares outstanding.

As of June 30, 2026, Zhejiang Jingxin Pharmaceutical Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 13.48. The price-to-sales ratio is 2.51, and the price-to-book ratio stands at 1.79.

As of June 30, 2026, Zhejiang Jingxin Pharmaceutical Co., Ltd. Class A trades at an EV/EBITDA multiple of 11.29 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.43 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 11.29 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 9.89B versus a market cap of 10.75B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Zhejiang Jingxin Pharmaceutical Co., Ltd. Class A maintains a current ratio of 2.48, meaning it holds 2.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 3.48, indicating elevated leverage, while an interest coverage ratio of 405.99 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Zhejiang Jingxin Pharmaceutical Co., Ltd. Class A posted a return on equity (ROE) of 12.98, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 12.51 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 9.52, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 12.31, useful for judging operating efficiency across full business cycles. The company generates approximately 1.08M in revenue per employee across its workforce of 3,766.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.47 indicates how many times Zhejiang Jingxin Pharmaceutical Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Zhejiang Jingxin Pharmaceutical Co., Ltd. Class A recorded 100.96M in income tax expense. That works out to an effective tax rate of 11.62, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 868.99M, leaving 758.58M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Zhejiang Jingxin Pharmaceutical Co., Ltd. Class A's stock has declined approximately 37.52% over the past 52 weeks. The 50-day moving average sits at 12.35, while the 200-day moving average is 14.65.

Over the twelve months ended June 30, 2026, Zhejiang Jingxin Pharmaceutical Co., Ltd. Class A generated 4.07B in revenue and converted that into 758.58M in net income, yielding earnings per share of 0.94. EBITDA reached 875.88M, while operating income came in at 920.00M.

As of June 30, 2026, Zhejiang Jingxin Pharmaceutical Co., Ltd. Class A holds 1.12B in cash and equivalents against 210.30M in total debt, resulting in a net debt position of -315.85M. Total book value stands at 6.00B, with working capital of 2.32B providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Zhejiang Jingxin Pharmaceutical Co., Ltd. Class A posted a gross margin of 50.67, reflecting its pricing power and cost economics. The operating margin of 22.61 and net profit margin of 18.64 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Zhejiang Jingxin Pharmaceutical Co., Ltd. Class A paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 6.03, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Zhejiang Jingxin Pharmaceutical Co., Ltd. Class A shareholders.

Zhejiang Jingxin Pharmaceutical Co., Ltd. Class A's most recent stock split took place on May 28, 2021 with a 5:6 split ratio.

As of June 30, 2026, Zhejiang Jingxin Pharmaceutical Co., Ltd. Class A has an Altman Z-Score of 5.41, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.